Calithera Biosciences (CALA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Calithera Biosciences (NASDAQ:CALA) have earned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $17.67.

Several analysts have recently commented on CALA shares. Citigroup upgraded shares of Calithera Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the company from $6.95 to $14.00 in a report on Friday, February 16th. Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Leerink Swann reiterated an “outperform” rating on shares of Calithera Biosciences in a report on Friday. BidaskClub upgraded shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, December 22nd. Finally, ValuEngine downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, February 3rd.

How to Become a New Pot Stock Millionaire

A number of hedge funds and other institutional investors have recently bought and sold shares of CALA. Trexquant Investment LP purchased a new stake in Calithera Biosciences during the third quarter worth about $168,000. Wells Fargo & Company MN increased its holdings in Calithera Biosciences by 25.8% during the third quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock worth $531,000 after buying an additional 6,910 shares during the last quarter. California Public Employees Retirement System increased its holdings in Calithera Biosciences by 210.1% during the third quarter. California Public Employees Retirement System now owns 43,719 shares of the biotechnology company’s stock worth $689,000 after buying an additional 29,619 shares during the last quarter. Franklin Street Advisors Inc. NC increased its holdings in Calithera Biosciences by 56.2% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 55,580 shares of the biotechnology company’s stock worth $464,000 after buying an additional 20,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Calithera Biosciences by 56.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 112,235 shares of the biotechnology company’s stock worth $938,000 after buying an additional 40,635 shares during the last quarter. Institutional investors and hedge funds own 68.37% of the company’s stock.

Shares of CALA stock opened at $5.45 on Wednesday. The stock has a market capitalization of $195.15, a PE ratio of -6.49 and a beta of 2.62. Calithera Biosciences has a one year low of $5.35 and a one year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, March 8th. The biotechnology company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.09). The firm had revenue of $7.24 million during the quarter, compared to analysts’ expectations of $7.28 million. Calithera Biosciences had a negative net margin of 107.21% and a negative return on equity of 17.49%. During the same quarter in the prior year, the company earned ($0.45) EPS. sell-side analysts expect that Calithera Biosciences will post -1.21 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Calithera Biosciences (CALA) Given Consensus Recommendation of “Hold” by Brokerages” was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3343378/calithera-biosciences-cala-given-consensus-recommendation-of-hold-by-brokerages.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

The Providence Service  Upgraded at BidaskClub
The Providence Service Upgraded at BidaskClub
Kinder Morgan’s  Buy Rating Reiterated at Bank of America
Kinder Morgan’s Buy Rating Reiterated at Bank of America
Spectrum Brands  Price Target Cut to $112.00
Spectrum Brands Price Target Cut to $112.00
Texas Capital Bancshares  Given New $100.00 Price Target at SunTrust Banks
Texas Capital Bancshares Given New $100.00 Price Target at SunTrust Banks
Alcoa  Price Target Increased to $0.00 by Analysts at JPMorgan Chase
Alcoa Price Target Increased to $0.00 by Analysts at JPMorgan Chase
Autodesk  Price Target Increased to $150.00 by Analysts at Oppenheimer
Autodesk Price Target Increased to $150.00 by Analysts at Oppenheimer


Leave a Reply

© 2006-2018 Ticker Report. Google+.